Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia
Wendy Stock,Barthelemy Diouf,Kristine R. Crews,Deqing Pei,Cheng Cheng,Kristina Laumann,Sumithra J. Mandrekar,Sumithra J. Mandrekar,Selina M. Luger,Anjali S. Advani,Richard Stone,Richard A. Larson,Richard A. Larson,William E. Evans +13 more
TL;DR: The CEP72 polymorphism can identify adults at increased risk of vincristine‐induced peripheral neuropathy and was significantly higher in patients homozygous for the CEP 72 T/T genotype.
Journal ArticleDOI
Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer.
Tejaswi Kandula,Tejaswi Kandula,Michelle A. Farrar,Michelle A. Farrar,Matthew C. Kiernan,Arun V. Krishnan,David Goldstein,Lisa G. Horvath,Lisa G. Horvath,Peter Grimison,Frances M. Boyle,Frances M. Boyle,Sally Baron-Hay,Susanna B. Park,Susanna B. Park +14 more
TL;DR: Current understanding of neurophysiological changes that underlie the development of neuropathy, clinical presentations and patient reported outcomes are summarized as well as advantages and limitations of current techniques for the neurophysiology assessment of CIPN are summarised.
Journal ArticleDOI
ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review
Geerard L. Beets,David Sebag-Montefiore,Elisabeth Andritsch,Dirk Arnold,Marc Beishon,Mirjam Crul,Jan Willem T. Dekker,Roberto Delgado-Bolton,Jean François Fléjou,Wolfgang Grisold,Geoffrey Henning,Andrea Laghi,József Lövey,Anastassia Negrouk,Philippe L. Pereira,Pierre Roca,Tiina Saarto,Thomas Seufferlein,Claire Taylor,Giampaolo Ugolini,Cornelis J.H. van de Velde,Bert van Herck,Wendy Yared,Alberto Costa,Peter Naredi +24 more
TL;DR: Taken together, the information presented in this paper provides a comprehensive description of the essential requirements for establishing a high-quality CRC service.
Journal ArticleDOI
Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy.
J. Matt McCrary,David Goldstein,Carolina X. Sandler,Carolina X. Sandler,Carolina X. Sandler,Benjamin K. Barry,Benjamin K. Barry,Michael Marthick,Hannah C. Timmins,Tiffany Li,Lisa G. Horvath,Lisa G. Horvath,Peter Grimison,Peter Grimison,Susanna B. Park,Susanna B. Park +15 more
TL;DR: This study provides encouraging evidence of the rehabilitative potential of multimodal exercise for persisting CIPN in a post-treatment cohort and large randomised controlled trials are justified to confirm observed benefits and determine the mechanisms and clinical significance.
Journal ArticleDOI
A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN)
TL;DR: An oral B group vitamin as an adjunct to neurotoxic chemotherapy regimens was not superior to placebo (p > 0.05) for the prevention of CIPN, but a trend was observed indicating that vitamin B12 may reduce the onset and severity of C IPN.
References
More filters
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values
Roman Rolke,Ralf Baron,Christoph Maier,Thomas R. Tölle,Rolf-Detlef Treede,Antje Beyer,Andreas Binder,Niels Birbaumer,Frank Birklein,I. C. Bötefür,S. Braune,Herta Flor,Volker Huge,R. Klug,G. B. Landwehrmeyer,Walter Magerl,Christian Maihöfner,C. Rolko,C. Schaub,Andrea Scherens,Till Sprenger,Michael Valet,B. Wasserka +22 more
TL;DR: Application of this standardized QST protocol in patients and human surrogate models will allow to infer underlying mechanisms from somatosensory phenotypes as well as judge plus or minus signs in patients.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more